Cited 50 times in
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2021-09-29T01:54:09Z | - |
dc.date.available | 2021-09-29T01:54:09Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184607 | - |
dc.description.abstract | Purpose: Pembrolizumab demonstrated efficacy in PD-L1-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (G/GEJ) cancer in the first-, second-, and third-line setting in KEYNOTE-062, KEYNOTE-061, and KEYNOTE-059, respectively. To better delineate the specificity of CPS as a predictor of clinical outcomes, we analyzed pembrolizumab efficacy in patients with CPS ≥ 10 in these trials. Patients and methods: Included were patients with CPS ≥ 10 tumors from KEYNOTE-059 cohort 1 (pembrolizumab, n = 46; post hoc), KEYNOTE-061 (pembrolizumab, n = 53; chemotherapy, n = 55; post hoc), and KEYNOTE-062 (pembrolizumab, n = 92; chemotherapy, n = 90; primary). Efficacy outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR). Results: In KEYNOTE-059, median follow-up was 6 months, median OS was 8 months [95% confidence interval (CI), 5.8-11.1], ORR was 17%, and median (range) DOR was 21 months (3+ to 35+). In KEYNOTE-061, median follow-up was 9 months, median OS (pembrolizumab vs. chemotherapy) was 10 versus 8 months (HR, 0.64; 95% CI, 0.41-1.02), median PFS was 3 months versus 3 months (HR, 0.86; 95% CI, 0.56-1.33), ORR was 25% versus 9%, and median (range) DOR was not reached (4 to 26+ months) versus 7 months (3-7). In KEYNOTE-062, median follow-up was 11 months, median OS (pembrolizumab vs. chemotherapy) was 17 months versus 11 months (HR, 0.69; 95% CI, 0.49-0.97), median PFS was 3 months versus 6 months (HR, 1.09, 95% CI; 0.79-1.49), ORR was 25% versus 38%, and median (range) DOR was 19 months (1+ to 34+) versus 7 months (2+ to 30+). Conclusions: This comprehensive analysis showed consistent improvements toward more favorable clinical outcomes with pembrolizumab across lines of therapy in patients with CPS ≥ 10 G/GEJ cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | American Association for Cancer Research | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Zev A Wainberg | - |
dc.contributor.googleauthor | Charles S Fuchs | - |
dc.contributor.googleauthor | Josep Tabernero | - |
dc.contributor.googleauthor | Kohei Shitara | - |
dc.contributor.googleauthor | Kei Muro | - |
dc.contributor.googleauthor | Eric Van Cutsem | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Kensei Yamaguchi | - |
dc.contributor.googleauthor | Eniko Varga | - |
dc.contributor.googleauthor | Jen-Shi Chen | - |
dc.contributor.googleauthor | Daniel Hochhauser | - |
dc.contributor.googleauthor | Peter Thuss-Patience | - |
dc.contributor.googleauthor | Salah-Eddin Al-Batran | - |
dc.contributor.googleauthor | Marcelo Garrido | - |
dc.contributor.googleauthor | Uma Kher | - |
dc.contributor.googleauthor | Chie-Schin Shih | - |
dc.contributor.googleauthor | Sukrut Shah | - |
dc.contributor.googleauthor | Pooja Bhagia | - |
dc.contributor.googleauthor | Joseph Chao | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-20-2980 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 33446564 | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1923 | - |
dc.citation.endPage | 1931 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.27(7) : 1923-1931, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.